Analytical methods | ||
---|---|---|
Comparative study | #1 | |
Chromatography | LC | |
Ion source | AFADESI | |
Positive/Negative mode | positive, negative | |
Mass analyzer | Q-Orbitrap, Q-TOF | |
Identification level | MS/MS |
Sample information | ||
---|---|---|
Comparative study | #1 | |
Country | China | |
Specimen | tissue | |
Marker function | diagnosis | |
Participants(Case) | Cancer type | adenocarcinoma, squamous cell carcinoma |
Stage | – | |
Number | 52 | |
Gender (M,F) | – | |
Mean age (range) (M,F) | – | |
Smoking status | – | |
Participants(Control) | Type | tumor vs. adjacent normal tissue |
Number | 21.0 | |
Gender (M,F) | – | |
Mean age (range) (M,F) | – | |
Smoking status | – |
Data processing and metabolite identification | |
---|---|
Data processing software | Markerview (AB SCIEX) |
Database search | LIPID MAPS, Massbank, HMDB, METLIN |
Statistics and concentration information | |
---|---|
Differential analysis method | t-test, PLS-DA, OPLS-DA |
Classification method | ROC curve analysis |
Survival analysis method | – |
Metabolite | Comparative study | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
---|---|---|---|---|---|---|---|---|
betaine | – | – | – | – | – | – | – | 2.55 |
choline | – | V | – | – | – | – | – | 14 |
L-carnitine | – | – | – | – | – | – | – | 3.72 |
PC(16:0/18:1) | – | – | – | – | – | – | – | 14.08 |
PC(16:0/18:1) | – | – | – | – | – | – | – | 13.36 |
PC(16:0/18:2) | – | – | – | – | – | – | – | 8.58 |
PC(16:0/18:2) | – | – | – | – | – | – | – | 6.35 |
PC(16:0/20:4) | – | V | – | – | – | – | – | 6.23 |
PC(18:0/18:1) | – | – | – | – | – | – | – | 8.36 |
PC(18:0/18:2) | – | – | – | – | – | – | – | 8.83 |
PC(18:1/18:1) | – | – | – | – | – | – | – | 8.21 |
PC(18:1/20:3) | – | V | – | – | – | – | – | 5.89 |
PC(32:1) | – | – | – | – | – | – | – | 7.32 |
PC(32:1) | – | – | – | – | – | – | – | 5.06 |
PC(34:0) | – | – | – | – | – | – | – | 8.94 |
PC(34:1) | – | V | – | – | – | – | – | 9.24 |
PC(36:1) | – | – | – | – | – | – | – | 6.47 |
PC(36:3) | – | V | – | – | – | – | – | 7.05 |
PC(38:2) | – | V | – | – | – | – | – | 5.13 |
PC(O-16:0/18:1) | – | – | – | – | – | – | – | 5.74 |
PC(O-34:1) | – | – | – | – | – | – | – | 5.11 |
PC(P-18:0/18:0) | – | – | – | – | – | – | – | 6.78 |
PC(P-34:1) | – | – | – | – | – | – | – | 3.37 |
proline | – | – | – | – | – | – | – | 2.01 |
Metabolite | Comparative study | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
---|---|---|---|---|---|---|---|
betaine | – | – | – | – | – | – | – |
choline | – | V | – | – | – | – | – |
L-carnitine | – | – | – | – | – | – | – |
PC(16:0/18:1) | – | – | – | – | – | – | – |
PC(16:0/18:1) | – | – | – | – | – | – | – |
PC(16:0/18:2) | – | – | – | – | – | – | – |
PC(16:0/18:2) | – | – | – | – | – | – | – |
PC(16:0/20:4) | – | V | – | – | – | – | – |
PC(18:0/18:1) | – | – | – | – | – | – | – |
PC(18:0/18:2) | – | – | – | – | – | – | – |
PC(18:1/18:1) | – | – | – | – | – | – | – |
PC(18:1/20:3) | – | V | – | – | – | – | – |
PC(32:1) | – | – | – | – | – | – | – |
PC(32:1) | – | – | – | – | – | – | – |
PC(34:0) | – | – | – | – | – | – | – |
PC(34:1) | – | V | – | – | – | – | – |
PC(36:1) | – | – | – | – | – | – | – |
PC(36:3) | – | V | – | – | – | – | – |
PC(38:2) | – | V | – | – | – | – | – |
PC(O-16:0/18:1) | – | – | – | – | – | – | – |
PC(O-34:1) | – | – | – | – | – | – | – |
PC(P-18:0/18:0) | – | – | – | – | – | – | – |
PC(P-34:1) | – | – | – | – | – | – | – |
proline | – | – | – | – | – | – | – |